How do you approach a young patient with undifferentiated pleomorphic sarcoma of the upper extremity who developed ifosfamide-induced nephrotoxicity after two cycles of adjuvant AIM chemotherapy?
Would you consider stopping therapy versus doxorubicin + dacarbazine/doxorubicin alone versus alternative chemotherapy ?
Answer from: Medical Oncologist at Academic Institution
In the adjuvant setting, I would suggest to stop further therapy and observe the patient. There is no clear survival benefit with the use of adjuvant therapy. However, I do say this with the knowledge that Sarculator-based analysis of EORTC-STBSG 62931 has demonstrated an OS benefit in patients rece...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
If the treatment is strictly adjuvant, OK to stop the chemotherapy. Might consider radiotherapy if not done pre-op.
Comments
Medical Oncologist at Rutgers Cancer Institute of New Jersey
With the controversy regarding adjuvant chemothera...
With the controversy regarding adjuvant chemothera...